AER-271 (AER271)
- Product Name
- AER-271 (AER271)
- CAS No.
- 634913-39-6
- Chemical Name
- AER-271 (AER271)
- Synonyms
- AER-271;AER-271 (AER271);AER-271, 10 mM in DMSO;Benzamide, N-[3,5-bis(trifluoromethyl)phenyl]-5-chloro-2-(phosphonooxy)-;(2-{[3,5-bis(trifluoromethyl)phenyl]carbamoyl}-4-chlorophenoxy)phosphonic acid;2-((3,5-Bis(trifluoromethyl)phenyl)carbamoyl)-4-chlorophenyl dihydrogen phosphate;Inhibitor,AER-271,AQP4,AER-270,stroke,inhibit,aquaporin-4,injury,AER 271,acute,AER271,CNS,ischemic
- CBNumber
- CB74844445
- Molecular Formula
- C15H9ClF6NO5P
- Formula Weight
- 463.65
- MOL File
- 634913-39-6.mol
AER-271 (AER271) Property
- Density
- 1.692±0.06 g/cm3(Predicted)
- storage temp.
- -20°C
- solubility
- DMSO:125.0(Max Conc. mg/mL);269.6(Max Conc. mM)
- pka
- 0.97±0.50(Predicted)
- form
- Solid
- color
- White to off-white
Hazard and Precautionary Statements (GHS)
- Symbol(GHS)
-
- Signal word
- Warning
- Hazard statements
-
H302Harmful if swallowed
H315Causes skin irritation
H319Causes serious eye irritation
H335May cause respiratory irritation
- Precautionary statements
-
P261Avoid breathing dust/fume/gas/mist/vapours/spray.
P280Wear protective gloves/protective clothing/eye protection/face protection.
P301+P312IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P302+P352IF ON SKIN: wash with plenty of soap and water.
P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.
N-Bromosuccinimide Price
- Product number
- SML2737
- Product name
- AER-271
- Purity
- ≥98% (HPLC)
- Packaging
- 5MG
- Price
- $85
- Updated
- 2025/07/31
- Product number
- SML2737
- Product name
- AER-271
- Purity
- ≥98% (HPLC)
- Packaging
- 25MG
- Price
- $345
- Updated
- 2025/07/31
- Product number
- orb611312
- Product name
- AER-271
- Purity
- >98%
- Packaging
- 100mg
- Price
- $1133.9
- Updated
- 2021/12/16
- Product number
- orb611312
- Product name
- AER-271
- Purity
- >98%
- Packaging
- 250mg
- Price
- $1949.9
- Updated
- 2021/12/16
- Product number
- orb611312
- Product name
- AER-271
- Purity
- >98%
- Packaging
- 1g
- Price
- $3876
- Updated
- 2021/12/16
AER-271 (AER271) Chemical Properties,Usage,Production
Uses
AER-271, a phosphonate proagent derivative of AER-270, is an aquaporin-4 (AQP4) inhibitor for the research of acute ischemic stroke[1].
Biological Activity
AER-271 is a phosphonate precursor (prodrug) form of the selective aquaporin 4 (AQP4) inhibitor IMD-0354 (AER-270; hu/m/r IC50 = 420/390/210 nM using respective CHO AQP4 transfectants) with >5000-fold enhanced solubility. AER-271 is rapidly converted to AER-270 in vivo (plasma AER-270 Cmax = 500 ng/mL or 1.75 μM, 20 min post 10 mg AER-271/kg i.p.; C57BL/6 mice) and exhibits therapeutic efficacy in rodent models of brain damage by cardiac arrest or ischemic stroke (5-10 mg/kg ip. & 0.08 mg/h sc. in mice; 1-10 mg/kg iv. in rats).
in vivo
AER-271 is converted in vivo to AER-270 by endogenous phosphatases. AER-271 blocks acute cerebral edema and improves early outcome in a pediatric model of asphyxial cardiac arrest[1].
AER-271 reduces cerebral edema and improves neurological outcomes in rodent ischemic stroke models. Mice treated with AER-271 (5 mg/kg; i.p. injection) show improved outcomes and reduced cerebral edema in a model of ischemic stroke[2].
| Animal Model: | Male mice (C57BL/6J, 8-12?week-old, 25-30?g)[2] |
| Dosage: | 5?mg/kg |
| Administration: | Treated by i.p. injection |
| Result: | Had better outcomes with an average neurological score of 0.89±0.31 compared with control mice receiving vehicle had an average neurological score of 2.50±0.62. |
References
[1] Wallisch JS, et al. The aquaporin-4 inhibitor AER-271 blocks acute cerebral edema and improves early outcome in a pediatric model of asphyxial cardiac arrest. Pediatr Res. 2019 Mar;85(4):511-517. DOI:10.1038/s41390-018-0215-5
[2] Farr GW, et al. Functionalized Phenylbenzamides Inhibit Aquaporin-4 Reducing Cerebral Edema and Improving Outcome in Two Models of CNS Injury. Neuroscience. 2019 Apr 15;404:484-498. DOI:10.1016/j.neuroscience.2019.01.034